HPTN 032

Male Tolerance Study of BufferGel and PRO 2000/5 Gel (P)

Study Summary

What was HPTN 032?

A Phase I, randomized, blinded, crossover study to assess the toxicity and acceptability of a topical microbicide when applied to the penis of HIV-infected men.

Who participated in the study?

12 circumcised and 12 uncircumcised HIV-infected men residing in the Seattle, WA area.

What happened during the study?

Nightly application of 2 mL of BufferGel, PRO 2000/5 Gel (P), or placebo gel for a period of seven consecutive nights each. Gel was applied to the shaft and glans of the penis at bedtime, left on for a minimum of six hours, and washed off the next morning.

Results

The daily application of the study's topical microbicide products directly to the penis consecutively for 7 days was generally safe and well tolerated among men participating in the study.

Study Documents

Study Details

Protocol Status: Concluded
Study Purpose:

To assess the toxicity and acceptability of BufferGel and PRO 2000/5 Gel (P) when applied to the penis of HIV-infected men, compared to a placebo control gel.

Study Design:

Phase I, randomized, blinded, crossover study with one week of exposure to each of BufferGel, PRO 2000 Gel (P), and a placebo control gel. Each week of exposure is separated by a one-week washout period.

Study Population:

Circumcised and uncircumcised HIV-infected men residing in the Seattle, WA area.

Study Size:

24 participants total (12 circumcised, 12 uncircumcised)

Study Duration:

Approximately eight months total. Accrual required six-and-a-half months and each participant is followed for a minimum of five weeks.

Treatment Regimen:

Nightly application of 2 mL of BufferGel, PRO 2000/5 Gel (P), or placebo gel for a period of seven consecutive nights each. Gel is applied to the shaft and glans of the penis at bedtime, left on for a minimum of six hours, and washed off the next morning.

Primary Objectives:

To assess the toxicity of BufferGel and PRO 2000/5 Gel (P) on the penile epithelium and urethral mucosa of HIV-infected men.

Secondary Objectives:

To assess the acceptability of BufferGel and PRO 2000/5 Gel (P) among HIV-infected men.

Key Study Personnel

Connie Celum, Protocol Chair

Study Sites List